Hematopoietic stem cell screening method, hematopoietic stem cell population production method, and hematopoietic stem cell screening kit
The use of miRNA-responsive mRNA switches allows for precise selection and enrichment of hematopoietic stem cells with high self-renewal and multipotency, addressing the challenges of purity and genome damage in existing methods, and enhancing clinical suitability.
Patent Information
- Application Number
- PCT/JP2024/018347
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for selecting hematopoietic stem cells face challenges in achieving high purity and avoiding genome damage, particularly in clinical applications, and lack a specific process for selecting cells with high self-renewal and multipotency.
A method involving the introduction of miRNA-responsive mRNA switches that turn off translation in response to specific miRNAs, allowing for precise selection of hematopoietic stem cells using markers encoded by these switches, without integrating into the genome, and a kit comprising these switches for cell population enrichment.
Enables the selection of hematopoietic stem cells with high self-renewal and multipotency with high precision and purity, reducing the risk of genome damage and improving clinical applicability.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Method for selecting hematopoietic stem cells, method for producing a hematopoietic stem cell population, and kit for selecting hematopoietic stem cells
[0001] The present invention relates to a method for selecting hematopoietic stem cells using an miRNA-responsive mRNA switch, a method for producing a hematopoietic stem cell population, and a kit used therefor.
[0002] The tissues and organs of multicellular organisms are composed of many different types of cells. Humans are made up of approximately 411 different types of mature cells alone. The technology to select only target cells from a population of cell types with different properties is extremely important for regenerative medicine. Among these cells, hematopoietic stem cells possess both pluripotency and the ability to self-replicate, allowing them to differentiate into all blood cells. Clinically, autologous and allogeneic transplants of hematopoietic stem cells are performed to treat diseases such as leukemia, malignant lymphoma, multiple myeloma, and aplastic anemia.
[0003] In a study of gene therapy using hematopoietic stem cells, it has been reported that reporter vectors were used to quantify miRNA activity in hematopoietic stem cells, providing a basis for the future isolation of human hematopoietic stem cells that contain miRNAs as functional biomarkers (see, for example, Non-Patent Document 1).
[0004] The present applicants have developed a method for distinguishing cells using RNA switch technology, which uses mRNA that responds to endogenous miRNA and turns off the translation of the protein it encodes (see, for example, Patent Document 1).
[0005] International Publication WO2015 / 105172
[0006] Science Translational Medicine, 2010, 2 (58), 58ra84.
[0007] The method disclosed in Non-Patent Document 1 uses a reporter construct delivered by a vector. Such a reporter construct may be integrated into the genome of target cells and cause unexpected genomic damage. This may pose a problem in clinical application. Furthermore, the method disclosed in Patent Document 1 does not establish a specific process for selecting hematopoietic stem cells with high self-renewal ability and pluripotency.
[0008] There is a need for a method for selecting highly pure viable hematopoietic stem cells with high self-renewal and pluripotency without the risk of genomic damage.
[0009] As a result of extensive research, the inventors discovered that by introducing into a cell population an mRNA switch mRNA whose translation is turned off in response to a specific miRNA, it becomes possible to select cells with high accuracy, and thus completed the present invention.
[0010] That is, the present invention includes the following aspects: [1] (i) A method for selecting hematopoietic stem cells, comprising the step of introducing a first miRNA-responsive mRNA switch into a cell population, wherein the first miRNA-responsive mRNA switch is an mRNA molecule in which (a) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p and (b) a nucleic acid sequence encoding a first marker protein are operably linked. [2] The step (i) further comprises a step of introducing a second miRNA-responsive mRNA switch into the cell population, wherein the second miRNA-responsive mRNA switch comprises: (A) a nucleic acid sequence specifically recognized by any one mouse miRNA sequence selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p, or any one human miRNA sequence selected from hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, and hsa-miR-223-3p; (B) an mRNA molecule operably linked to a nucleic acid sequence encoding a second marker protein, wherein the first marker protein and the second marker protein are different. [3] The method of [2], wherein the second miRNA-responsive mRNA switch is co-introduced with the first miRNA-responsive mRNA switch. [4] The method of [1], further comprising (ii) a step of selecting hematopoietic stem cells based on the expression level of the first marker protein. [5] The method of [4], further comprising (iii) a step of culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell expansion medium. [6] The method of [2], further comprising (ii) a step of selecting hematopoietic stem cells based on the expression levels of the first and second marker proteins. [7] The method of [6], further comprising (iii) a step of culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell expansion medium.[8] The method according to [1], comprising a step of obtaining a hematopoietic stem cell population selected based on a cell surface marker before or after step (i). [9] A method for producing a hematopoietic stem cell population, comprising a step of obtaining a selected hematopoietic stem cell population by the selection method according to [1].
[10] A kit for selecting hematopoietic stem cells, comprising a first miRNA-responsive mRNA switch, wherein the first miRNA-responsive mRNA switch is an mRNA molecule operably linked to: (a) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p, and (b) a nucleic acid sequence encoding a first marker protein.
[11] A method for producing a nucleic acid sequence encoding a second miRNA-responsive mRNA switch, further comprising: (A) a nucleic acid sequence specifically recognized by any one mouse miRNA sequence selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p; or any one human miRNA sequence selected from hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, and hsa-miR-223-3p; and (B) a nucleic acid sequence encoding a second marker protein. and a second marker protein operably linked thereto, wherein the second marker protein is different from the first marker protein.
[12] A hematopoietic stem cell population enriched for cells that are mmu-miR-126a-3p or hsa-miR-126-3p activity-positive and mmu-miR-130a-3p or hsa-miR-130a-3p activity-positive.
[13] The hematopoietic stem cell population according to
[12] , which is hsa-miR-126-3p activity-positive and hsa-miR-130a-3p activity-positive, for use in human living donor transplantation.
[0011] According to the method for selecting hematopoietic stem cells or the method for producing a selected hematopoietic stem cell population of the present invention, hematopoietic stem cells having high self-renewal ability and pluripotency can be obtained with high accuracy.
[0012] Figure 1 shows an outline of an experiment in which miRNA activity was measured in ex vivo cultured mouse hematopoietic stem cells using a miRNA-responsive mRNA switch capable of detecting intracellular miRNA activity. Figure 2A shows the results of measuring miR-126a-3p activity in ex vivo cultured mouse hematopoietic stem cells. The plots show EGFP vs. TagBFP and histograms of EGFP / TagBFP for cells transfected with control EGFP mRNA (top row) and cells transfected with the miR-126a-3p-responsive miRNA switch (bottom row). Figure 2B shows the percentage of miR-126a-3p-positive cells. n=2. Black bars represent the average of two independent experiments. Figure 3A shows a histogram of EGFP / TagBFP for cells transfected with EGFP mRNA or the miR-126a-3p-responsive miRNA switch and a miR-126a-3p inhibitor. Figure 3B shows the percentage of miR-126a-3p-positive cells in cells transfected with EGFP mRNA or a miR-126a-3p-responsive miRNA switch and a miR-126a-3p inhibitor. Figure 4 shows the results of analyzing cell surface markers expressed by miR-126a-3p activity-positive and -negative cells. Figure 5A shows the percentage of miR-126a-3p-positive cells in cells transfected with a miR-126a-3p inhibitor and a miR-126a-3p-responsive miRNA switch. + Figure 5B is a schematic diagram showing that EPCR is contained in the KSL fraction. + Figure 6 shows the gating for FACS sorting of KSL fractions. + Figure 7 shows the percentage of miR-126a-3p activity-positive and -negative cells in the KSL fraction. Figure 7 shows an outline of the experiment to evaluate the function of miR-126a-3p activity-positive and -negative cells by transplantation assay. Figure 8A is a graph showing the transition of peripheral blood chimerism (PB chimerism %) over the number of weeks since transplantation. Figure 8B shows the percentage of miR-126a-3p activity-positive and -negative cells in the KSL fraction. + cells, and miR-126a-3p -9A is a diagram illustrating the experimental scheme. FIG. 9B is a graph showing the transition of peripheral blood chimerism (PB chimerism %) over the number of weeks since transplantation. FIG. 9C is a graph showing the EPCR + KSL miR-126a-3p + Cells, and EPCR + KSL miR-126a-3p - 10 is a graph showing peripheral blood chimerism (PB chimerism %) 16 weeks after transplantation in cells. + KSL, EPCR - KSL, Sca-1 - Lineage - In a quantitative experiment of miRNA expression levels in fractions, EPCR was performed on mouse hematopoietic stem cells cultured in vitro for 2 weeks. + KSL, EPCR - KSL, Sca-1 - Lineage - Figure 11A shows the gating used to separate the fractions. + KSL, EPCR - KSL, Sca-1 - Lineage - Figure 11B shows the quantitative results of miRNA expression levels in the fractions. + KSL, EPCR - KSL, Sca-1 - Lineage - Figure 12A shows the quantitative results of miRNA expression levels in the fractions. + KSL, EPCR - KSL, Sca-1 - Lineage - Figure 12B shows the quantitative results of miRNA expression levels in the fractions. + KSL, EPCR - KSL, Sca-1 - Lineage -The figures show the results of quantifying miRNA expression levels in fractions. Figure 13A shows histograms with EGFP / TagBFP values on the vertical axis, obtained in experiments measuring the activity of miRNAs selected from miRNA expression level analysis using the Small RNA-seq method. Representative examples of histograms are shown for cells into which control EGFP mRNA or the miR-126a-3p-responsive miRNA switch was introduced. Figure 13B shows a bar graph showing the coefficient of variation (CV) of EGFP / TagBFP values in cell populations into which each of multiple candidate miRNAs was introduced. Figure 13B shows the EPCR - Compared to KSL, EPCR + Figure 13C shows a bar graph showing the coefficient of variation (CV) of EGFP / TagBFP values in cell populations transfected with each of several candidate miRNAs. + Compared to KSL, EPCR - Figure 14A shows the miRNAs highly expressed in KSL. Figure 14B shows the plot of EGFP / TagBFP on the vertical axis and mT-Sapphire / TagBFP on the horizontal axis, obtained from an experiment measuring the activity of two miRNAs simultaneously. Figure 14B shows the plot of EGFP / TagBFP on the vertical axis and mT-Sapphire / TagBFP on the horizontal axis, obtained from an experiment measuring the activity of two miRNAs simultaneously. Figure 15A shows the graph comparing the proliferation of cells after introducing the miRNA switch into cultured hematopoietic stem cells, sorting cells positive or negative for miR-126a-3p activity, and culturing them again in medium containing PVA. The graph shows the results of counting the number of cells recovered from a 250-cell derived culture. Figure 15B shows a graph comparing the proliferation of cells after introducing the miRNA switch into cultured hematopoietic stem cells, sorting cells with or without miR-126a-3p activity, and culturing them again in a medium containing PVA. The graph shows the results of counting the number of cells recovered from a 500-cell derived culture. Figure 16A shows an experimental scheme for selecting mouse hematopoietic stem cells using the activity of two types of miRNA as an indicator. Figure 16B shows the results of counting the number of cells recovered from a 500-cell derived culture. + miR-130a-3p+ Fractionation and miR-126a-3p + miR-130a-3p - Figure 16C shows the gating for FACS sorting of fractions. + miR-130a-3p + Cells and miR-126a-3p + miR-130a-3p - Figure 16D shows the results of a peripheral blood analysis after transplantation. Figure 16E shows the results of a cell function evaluation experiment. + miR-130a-3p + cells or miR-126a-3p + miR-130a-3p - Figure 17A shows a graph of peripheral blood chimerism (PB chimerism %) 12 weeks after transplantation in host mice transplanted with cells. Figure 17A shows an outline of an experiment using a miRNA switch to measure miRNA activity in human hematopoietic stem progenitor cells (HSPCs) cultured in vitro. Figure 17B shows the results of an experiment measuring the activity of hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-223-3p, or hsa-miR-10a-5p in human hematopoietic stem progenitor cells. Figure 18A shows an outline of an experiment measuring the activity of two miRNAs simultaneously in human hematopoietic stem progenitor cells. Figure 18B shows the results of an experiment measuring the activity of two miRNAs simultaneously in human hematopoietic stem progenitor cells.
[0013] Hereinafter, embodiments of the present invention will be described, but the present invention is not limited to the embodiments described below.
[0014] [First embodiment: Method for selecting hematopoietic stem cells using one type of miRNA switch] According to a first embodiment, the present invention provides a method for selecting a hematopoietic stem cell population, which comprises the following step (i): (i) introducing a first miRNA-responsive mRNA switch into a cell population;
[0015] The method for selecting a hematopoietic stem cell population may optionally include the following steps (ii) and / or (iii): (ii) selecting hematopoietic stem cells based on the expression level of a first marker protein encoded by the first miRNA-responsive mRNA, and (iii) culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell proliferation medium.
[0016] The method for producing a hematopoietic stem cell population may optionally include, prior to step (i), the following step: obtaining a hematopoietic stem cell population selected based on cell surface markers;
[0017] As used herein, "selecting hematopoietic stem cells" refers to selecting hematopoietic stem cells from a heterogeneous cell population that contains hematopoietic stem cells and may contain other cells, and making them distinguishable from other cells. Therefore, the selection method for hematopoietic stem cells according to this embodiment can also be considered a method for producing a selected hematopoietic stem cell population from another perspective. In one aspect, selecting hematopoietic stem cells refers to presenting detectable signal information for hematopoietic stem cells from a heterogeneous cell population that contains hematopoietic stem cells and may contain other cells, which is different from other cell types, and in particular, can refer to presenting visually recognizable information. Visually recognizable information is not limited to signals emitted by cells that can be directly seen, but refers to information obtained by converting signals emitted by cells into visually recognizable information such as numerical values, charts, or images, and refers to information visually recognizable by those skilled in the art. As used herein, the term "selecting" may include, after selection, recognizing a hematopoietic stem cell population, differentiating a hematopoietic stem cell population, identifying a hematopoietic stem cell population, classifying a hematopoietic stem cell population, isolating a hematopoietic stem cell population, removing cell types other than hematopoietic stem cells, determining the viability of hematopoietic stem cells, detecting or quantifying specific biological signals of hematopoietic stem cells, and fractionating hematopoietic stem cells based on specific physical or chemical signals.
[0018] "Hematopoietic stem cells" are cells that have the pluripotency to differentiate into all blood cells and are capable of self-renewal. Here, self-renewal means producing cells with the same functions and properties as the original cells through cell division. In other words, cells produced by the self-renewal of hematopoietic stem cells have the pluripotency to differentiate into all blood cells and the ability to self-renew. Because of these functions, hematopoietic stem cells have the ability to reconstruct bone marrow and continuously produce all blood cells when transplanted into an animal whose bone marrow has been destroyed. Hematopoietic stem cells are generally identified by cell surface markers and cluster of differentiation (CD). Murine hematopoietic stem cells generally express CD150 + , CD34 - , CD135 - , CD48 - , EPCR + , c-Kit + , Sca-1 + , and Lineage - Human hematopoietic stem cells are generally CD34 + , CD49f + , CD45RA - , CD90 / Thy1 + , CD38 low / - , c-Kit - / low , and Lineage - Based on these markers, hematopoietic stem cell populations can be separated by fluorescence-activated cell sorting (FACS).
[0019] In the method for selecting a hematopoietic stem cell population according to this embodiment, a step of obtaining a hematopoietic stem cell population selected based on cell surface markers can be carried out before or after the step of introducing the miRNA-responsive mRNA switch into the cell population. The selection of a hematopoietic stem cell population based on cell surface markers is as described above, and the mouse hematopoietic stem cell population is selected based on CD150 + , CD34 - , CD135 - , CD48 - , EPCR + , c-Kit + , Sca-1 + , and Lineage- Cells having a property selected from the above can be obtained by fluorescence-activated cell sorting (FACS). More specifically, the mouse hematopoietic stem cell population can be obtained by selecting cells having a property selected from the above by fluorescence-activated cell sorting (FACS). More specifically, the mouse hematopoietic stem cell population can be obtained by selecting cells having a property selected from the above by fluorescence-activated cell sorting (FACS). See, for example, Nature. 2018 Jan 24; 553(7689): 418-426. + , CD48 - , CD34 - , CD135 - , c-Kit + , Sca-1 + , and Lineage - In addition, mouse hematopoietic cell populations immediately after harvesting from bone marrow express CD150 + , CD34 - , c-Kit + , Sca-1 + , and Lineage - Set of CD150 + , CD48 - , c-Kit + , Sca-1 + , and Lineage - Human hematopoietic stem cell populations can be defined as cell populations identified using a set of CD34 + , CD49f + , CD45RA - , CD90 / Thy1 + , CD38 low / - , c-Kit - / low , and Lineage - Cells having a characteristic selected from the above can be obtained by fluorescence-activated cell sorting (FACS). The cell surface markers that identify a hematopoietic stem cell population may differ depending on the state of the target cell population, for example, whether or not it has been cultured, and those skilled in the art can refer to literature to identify a combination of cell surface markers that will select a specific hematopoietic stem cell population.
[0020] (i) Introduction Step Step (i) is a step of introducing a first miRNA-responsive mRNA switch into a cell population. In this embodiment, the "cell population" to be selected and into which the first miRNA-responsive mRNA switch is introduced refers to a collection of two or more cells that may include hematopoietic stem cells. The cell population may be a cell population collected from a multicellular organism. For example, it may be a cell population collected from umbilical cord blood, peripheral blood, or bone marrow of a mammal, particularly a human or mouse, or a cell population obtained by further culturing and expanding these. Alternatively, it may be cells (including cell lines) obtained by further artificially manipulating a cell population collected from a multicellular organism, but is not limited thereto. Artificial manipulation may include, but is not limited to, reprogramming, differentiation into specific cells after reprogramming, genome editing of intracellular molecules, or selection using an RNA switch. Genome-edited cells may be, for example, hematopoietic stem cells that have been genome-edited immediately after collection from a living organism or after a certain period of culture and expansion for the purpose of treating a hereditary blood disorder. The selection of the present invention can be carried out to select cells that retain the function of hematopoietic stem cells from such cells. It is also possible to introduce miRNA-responsive mRNA switches into cell populations whose presence or absence of hematopoietic stem cells is unknown.
[0021] The cell population may be, for example, a group of cells induced to differentiate from stem cells into hematopoietic stem cells. Examples of stem cells include, but are not limited to, embryonic stem (ES) cells, cloned embryonic stem (ntES) cells obtained by nuclear transfer, spermatogonial stem cells (GS cells), embryonic germ cells (EG cells), and induced pluripotent stem (iPS) cells. Among these, pluripotent stem cells such as ES cells and iPS cells are preferred, with iPS cells being particularly preferred. The method of inducing differentiation of hematopoietic stem cells from pluripotent stem cells can be carried out by any known method, including, for example, the method disclosed in Sugimura, R., Jha, D., Han, A. et al., "Haematopoietic stem and progenitor cells from human pluripotent stem cells." Nature 545, 432-438 (2017) and the method disclosed in Tan, Y.-T., et al., "Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor." Proc. Natl. Acad. Sci. USA 115, 2180-2185 (2018).
[0022] The miRNA-responsive mRNA switch introduced into a cell population refers to an mRNA molecule that, in the presence of specific miRNA activity, represses or activates the translation of a protein encoded by the mRNA. Herein, the term "miRNA-responsive mRNA switch" may be abbreviated as "miRNA switch." Furthermore, a miRNA-responsive mRNA switch that represses the translation of a protein encoded by the mRNA in the presence of specific miRNA activity and activates the translation of a protein encoded by the mRNA in the absence of specific miRNA activity may be referred to as an "OFF switch," while a miRNA-responsive mRNA switch that activates the translation of a protein encoded by the mRNA in the presence of specific miRNA activity and represses the translation of a protein encoded by the mRNA in the absence of specific miRNA activity may be referred to as an "ON switch."
[0023] In this embodiment, the first miRNA-responsive mRNA switch is an mRNA molecule in which the following nucleic acid sequence (a) and nucleic acid sequence (b) are operably linked, and is preferably an OFF switch: (a) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p, and (b) a nucleic acid sequence encoding a first marker protein. Hereinafter, the first miRNA-responsive mRNA switch will be referred to as the first miRNA switch.
[0024] In the first miRNA switch, the nucleic acid sequence (a) is preferably located on the 5' or 3' side of the nucleic acid sequence (b), and (a) and (b) are operably linked. A more specific structure of the first miRNA switch may be a structure in which a 5'-UTR, a coding region encoding a first marker protein, and a 3'-UTR are linked in the 5' to 3' direction of an mRNA molecule.
[0025] (a) mmu-miR-126a-3p is known to be one of the miRNAs active in mouse hematopoietic stem cells and is represented by ucguaccgugaguaauaaugcg (SEQ ID NO: 1). The miRNA active in human hematopoietic stem cells is hsa-miR-126-3p, whose sequence is identical to that of mmu-miR-126a-3p (SEQ ID NO: 2). "Active miRNA" in hematopoietic stem cells refers to a miRNA in which the mature miRNA interacts with multiple specific proteins to form an RNA-induced silencing complex (RISC). "Mature miRNA" is a single-stranded RNA (20-25 bases) that is generated outside the nucleus by cleavage by Dicer from pre-miRNA, which in turn is generated from pri-miRNA, a single-stranded RNA transcribed from DNA, by partial cleavage by a nuclear enzyme called Drosha.
[0026] The nucleic acid sequence (a) is also referred to herein as the "miRNA target sequence." The miRNA target sequence is preferably a sequence that is completely complementary to mmu-miR-126a-3p or hsa-miR-126-3p. Alternatively, the miRNA target sequence may have mismatches with the completely complementary sequence, as long as it can be recognized by mmu-miR-126a-3p or hsa-miR-126-3p. It is believed that mismatches of approximately 40-50% from the sequence completely complementary to the miRNA are acceptable for the intrinsic function of the miRNA in vivo. Examples of such mismatches include, but are not limited to, mismatches of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases, or mismatches of 1%, 5%, 10%, 20%, 30%, or 40% of the entire recognition sequence. Furthermore, miRNA target sequences on mRNAs contained in cells may contain multiple mismatches, particularly in portions other than the seed region, i.e., in the 5' region of the target sequence corresponding to approximately 16 bases on the 3' side of mmu-miR-126a-3p or hsa-miR-126-3p. The seed region may contain no mismatches or mismatches of one, two, or three bases. A miRNA switch having a human miRNA target sequence can be used for introduction into a human cell population, and a miRNA switch having a mouse miRNA target sequence can be used for introduction into a mouse cell population.
[0027] The nucleic acid sequence (b) is a nucleic acid sequence encoding a first marker protein. The marker protein is a protein that is expressed from the miRNA switch and functions as a marker in a cell, allowing the cell to be identified. Examples of marker proteins include proteins that can be visualized and quantified by fluorescence, luminescence, color development, or the assistance of fluorescence, luminescence, or color development. Examples of fluorescent proteins include blue fluorescent proteins such as Sirius and EBFP; cyan fluorescent proteins such as mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, and CFP; green fluorescent proteins such as TurboGFP, AcGFP, TagGFP, Azami-Green (e.g., hmAG1), ZsGreen, EmGFP, EGFP, GFP2, and HyPer; yellow fluorescent proteins such as TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, and mBanana; and KusabiraOrange. (e.g., hmKO2) and mOrange; red fluorescent proteins such as TurboRFP, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRed2, and mStrawberry; and near-infrared fluorescent proteins such as TurboFP602, mRFP1, JRed, KillerRed, mCherry, HcRed, KeimaRed (e.g., hdKeimaRed), mRasberry, and mPlum, but are not limited to these.
[0028] An example of a photoprotein is aequorin, but is not limited to this. Furthermore, examples of proteins that assist fluorescence, luminescence, or color development include enzymes that decompose fluorescent, luminescent, or color precursors, such as luciferase, phosphatase, peroxidase, beta-galactosidase, and beta-lactamase, but are not limited to these. When a protein that assists fluorescence, luminescence, or color development is used as a marker gene in the present invention, the desired cells can be identified by contacting the cells with the corresponding precursor or by introducing the corresponding precursor into the cells.
[0029] Other examples of marker proteins include proteins that directly affect cellular function. Examples include, but are not limited to, cell proliferation proteins, cell death proteins, cell signaling factors, drug resistance genes, transcriptional regulators, translational regulators, differentiation regulators, reprogramming inducers, RNA-binding protein factors, chromatin regulators, and membrane proteins. For example, cell proliferation proteins function as markers by promoting the proliferation of only cells that express them and identifying these proliferated cells. Cell death proteins cause cell death in expressing cells, thereby killing the cells themselves and functioning as markers indicating cell viability. Examples of cell death proteins include the RNase barnase and the proapoptotic proteins Bax and Bim. Cell signaling factors function as markers by identifying specific biological signals emitted by cells that express them. Examples include the transmembrane protein CD4, the low-affinity nerve growth factor receptor (LNGFR), and its loss-of-function mutant (ΔLNGFR). These cell signaling factors can be advantageously used as marker proteins for the purpose of fluorescently labeling cells using antibodies or biotin, and for the purpose of cell separation using magnetic beads.
[0030] According to a first embodiment of the first miRNA switch, the nucleic acid sequence (a) is located on the 5' side of the nucleic acid sequence (b). In this case, the 5'-UTR may have a structure in which a [cap structure or cap analog] and [the nucleic acid sequence (a)] are linked, in order from the 5' end. The cap structure may be 7-methylguanosine 5' phosphate. The cap analog is a modified structure that, like the cap structure, is recognized by the translation initiation factor eIF4E, and examples thereof include, but are not limited to, Ambion's Anti-Reverse Cap Analog (ARCA), New England Biolabs' m7G(5')ppp(5')G RNA Cap Structure Analog, and TriLink's CleanCap (registered trademark). CleanCap® AG and AU cap mRNA with the natural 5'-N7-methylguanosine 2'-O-methyl structure, while CleanCap® AG (3'-OMe) caps mRNA with the 5'-N7-methyl-3'-O-methylguanosine structure found in mRNA capped using the ARCA method. Cap analogs may also have other modified structures recognized by translation initiation factors.
[0031] The 3' side of the cap structure or cap analog, and the 5' side of the nucleic acid sequence (a), may contain an arbitrary nucleic acid sequence of, for example, about 0 to 50 bases, preferably about 0 to 30 bases. At least one nucleic acid sequence (a) may be contained, but two, three, four, or more repeats of the nucleic acid sequence (a) may be contained in the 5'-UTR. The 3' end of the 5'-UTR, which is the 3' side of the nucleic acid sequence (a), may contain an arbitrary nucleic acid sequence of, for example, about 0 to 50 bases, preferably about 10 to 30 bases. These arbitrary nucleic acid sequences are preferably nucleic acid sequences that do not form secondary structures. It is also preferable that the 5'-UTR does not contain an AUG, which serves as the start codon. For example, if the nucleic acid sequence (a) contains an AUG, frameshifting can be avoided by adding one or two bases to the end of the sequence. Alternatively, a stop codon sequence may be added outside the nucleic acid sequence (a), counting in 3-base increments from the AUG. Alternatively, one or more bases of AUG can be converted to any base as long as it does not affect the interaction with the protein.
[0032] The coding region of the first miRNA switch comprises the nucleic acid sequence of (b).
[0033] The 3'-UTR of the first miRNA switch comprises a PolyA tail. The total length of the PolyA tail may be 50 mers or more, and may contain nucleic acid bases other than A. Optionally, the 5' side of the PolyA tail may also contain the nucleic acid sequence of (a).
[0034] According to the second embodiment, the first miRNA switch has a nucleic acid sequence (a) located on the 3' side of a nucleic acid sequence (b). In this case, the 5'-UTR has a [cap structure or cap analog] at its 5' end and is composed of a nucleic acid sequence with a total base length of approximately 30 to 100. The nucleic acid sequence constituting the 5'-UTR in this case can be determined in the same manner as the arbitrary nucleic acid sequence of the first embodiment. The coding region of the first mRNA according to the second embodiment may be the same as the coding region of the first miRNA switch according to the first embodiment. The 3'-UTR of the first miRNA switch according to the second embodiment may have a structure in which, from the 5' end, [the nucleic acid sequence of (a)] and [a poly-A tail] are linked. Alternatively, the 3'-UTR of the first miRNA switch according to the second embodiment may have a structure in which [the nucleic acid sequence of (a)] is inserted into the poly-A tail. The first miRNA switch may have a structure that combines the first and second embodiments. In this case, both the 5'-UTR and the 3'-UTR have the nucleic acid sequence (a).
[0035] The first miRNA switch may have a modified sugar residue (ribose) of each nucleotide for purposes such as reducing cytotoxicity. Examples of the sugar residue modification include replacing the hydroxyl group or hydrogen atom at the 2', 3', and / or 4' positions of the sugar residue with other atoms. Examples of modifications include fluorination, alkoxylation (e.g., methoxylation, ethoxylation), O-allylation, S-alkylation (e.g., S-methylation, S-ethylation), S-allylation, and amination (e.g., -NH2). Such modifications of sugar residues can be carried out by methods known per se (see, for example, Sproat et al., (1991) Nucle. Acid. Res. 19, 733-738; Cotton et al., (1991) Nucl. Acid. Res. 19, 2629-2635; Hobbs et al., (1973) Biochemistry 12, 5138-5145).
[0036] The sugar residues of the first miRNA switch can also be bridged at the 2' and 4' positions to form a bridged nucleic acid (BNA) (linked nucleic acid) structure. Such sugar residue modifications can be performed by known methods (see, for example, Tetrahedron Lett., 38, 8735-8738 (1997); Tetrahedron, 59, 5123-5128 (2003); Rahman SMA, Seki S, Obika S, Yoshikawa H, Miyashita K, Imanishi T, J. Am. Chem. Soc., 130, 4886-4896 (2008)). The first miRNA switch can also have a modified nucleobase (e.g., purine, pyrimidine) (e.g., chemical substitution). Examples of such modifications include modification of the pyrimidine at position 5, modification of the purine at positions 6 and / or 8, modification with an exocyclic amine, substitution with 4-thiouridine, and substitution with 5-bromo- or 5-iodo-uracil. Furthermore, for the purpose of reducing cytotoxicity, modified bases such as pseudouridine (Ψ), N1-methylpseudouridine (N1mΨ), and 5-methylcytidine (5mC) may be contained in place of normal uridine or cytidine. The positions of the modified bases, whether uridine or cytidine, can be all or part of the bases independently, and if part of the bases are modified, they can be located at random positions in any proportion.
[0037] To improve resistance to nucleases and hydrolysis, the phosphate group (e.g., terminal phosphate residue) contained in the first miRNA switch may be modified. For example, the phosphate group P(O)O may be substituted with P(O)S (thioate), P(S)S (dithioate), P(O)NR2 (amidate), P(O)R, R(O)OR', CO, CH2 (formacetal), or 3'-amine (-NH-CH2-CH2-) (wherein each R or R' is independently H or substituted or unsubstituted alkyl (e.g., methyl, ethyl)). Examples of linking groups include -O-, -N-, and -S-, and adjacent nucleotides can be bound via these linking groups.
[0038] Once the molecular structure and nucleic acid sequence of the first miRNA switch have been determined as described above, those skilled in the art can synthesize it using any known genetic engineering method. For example, it can be obtained as a synthetic mRNA molecule by in vitro synthesis using a template DNA containing a promoter sequence. One advantage of the present invention is that it allows for the simple production of a designed synthetic mRNA molecule.
[0039] The introduction of the first miRNA switch into a cell population can be carried out using any method commonly used for introducing RNA molecules into cells. Methods for directly introducing RNA molecules into cells include, for example, lipofection, liposomes, electroporation, calcium phosphate coprecipitation, DEAE-dextran, microinjection, and gene gun techniques. The advantage of introducing synthetic RNA molecules is that they are not integrated into the genome, making it easier to use the cells after introducing the mRNA switch for medical applications.
[0040] The amount and ratio of the first miRNA switch introduced into a cell population are not limited to a specific amount. The first miRNA switch introduced into a cell population suppresses translation of a marker protein in cells in which mmu-miR-126a-3p or hsa-miR-126-3p is activated, and enables translation of the marker protein in cells in which mmu-miR-126a-3p or hsa-miR-126-3p is not activated.
[0041] (ii) Selection Step The selection step, which is an optional step following the introduction step, is a step of selecting hematopoietic stem cells based on the expression level of the first marker protein.
[0042] The expression level of a marker protein may include information on the presence or absence of translation of the marker protein, or quantitative information such as the expression level due to translation. When the marker protein is a protein that can be visualized and quantified by fluorescence, luminescence, color, or with the aid of fluorescence, luminescence, or color, specific cells can be separated and selected using, for example, a flow cytometer. When the marker protein is a protein that directly affects cell function, the presence or absence of translation of the marker protein can be detected as a change in cell function.
[0043] In step (ii) of this embodiment, based on the translation information of the marker protein, a cell population consisting of multiple cells into which an mmu-miR-126a-3p-responsive mRNA switch or an hsa-miR-126-3p-responsive mRNA switch has been introduced can be separated into two populations: cells with mmu-miR-126a-3p or hsa-miR-126-3p activity (mmu-miR-126a-3p or hsa-miR-126-3p positive cells) and cells with little or no mmu-miR-126a-3p or hsa-miR-126-3p activity (mmu-miR-126a-3p or hsa-miR-126-3p negative cells), and these cell populations with different characteristics can be identified.
[0044] For example, if the marker protein is an apoptosis protein, the apoptosis protein is translated and expressed in cells in which mmu-miR-126a-3p or hsa-miR-126-3p is not activated, thereby killing cells in which mmu-miR-126a-3p or hsa-miR-126-3p is not activated, i.e., cells that are presumed not to be hematopoietic stem cells, and hematopoietic stem cells can be selected without using equipment such as a cell sorter.
[0045] The selection step can generally be performed using a first miRNA switch based on the expression of a first marker protein, but selection can also be performed using an additional miRNA ON switch. In this case, for example, the first miRNA switch may be an OFF switch (hereinafter referred to as a lethal OFF switch) that has a miRNA target sequence that specifically recognizes mmu-miR-126a-3p or hsa-miR-126-3p and encodes a lethal protein as the first marker protein. The additional miRNA ON switch is an mRNA molecule (hereinafter referred to as an antilethal ON switch) that contains a miRNA target sequence that specifically recognizes mmu-miR-126a-3p or hsa-miR-126-3p and a nucleic acid sequence encoding the protein, and in cells in which these miRNAs are activated, expression of the encoded protein is activated.
[0046] More specifically, the antilethal ON switch is an ON switch mRNA that contains (a) a nucleic acid sequence encoding an antilethal gene that inactivates a lethal gene, (b) a PolyA tail located on the 3' side of (a), (c) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p located on the 3' side of (b), and (d) a translational repression sequence located on the 3' side of (c). The translational repression sequence is a nucleic acid sequence of five or more bases that can repress translation of the antilethal gene in the absence of an miRNA that specifically recognizes the nucleic acid sequence of (c). The translational repressor sequence may be, for example, a nucleic acid sequence of 5 to 10 bases comprising the same nucleic acid base; a nucleic acid sequence of 10 to 20 bases in which two or more nucleic acids with different nucleic acid bases are consecutively linked; a nucleic acid sequence of 30 to 50 bases in which two or more nucleic acids with different nucleic acid bases are consecutively linked; a nucleic acid sequence containing a repeat of a specific nucleic acid sequence of about 3 to 10 bases; a nucleic acid sequence of 20 or more bases that specifically recognizes a PolyA tail; or a nucleic acid sequence that specifically recognizes a 5'-UTR. Furthermore, the nucleic acid sequence of 5 or more bases may, in some cases, be a nucleic acid sequence of 10 or more, 20 or more, 30 or more, 40 or more, 50 or more, 100 or more, 300 or more, 500 or more, 1000 or more, or 1500 or more bases. The structure of a typical miRNA ON switch and a method for producing the same are disclosed in prior art WO2018 / 003779 by the present inventors, and those skilled in the art can produce a miRNA ON switch based on this disclosure.
[0047] The combination of a lethal protein and an antilethal protein is not particularly limited. For example, when the lethal protein is barnase derived from Bacillus amyloliquefaciens, an RNase, the antilethal protein can be barstar, a protein that inactivates RNase, derived from Bacillus amyloliquefaciens. Furthermore, when the lethal protein is apoptosis-inducing protein Bax (BCL2 associated X, apoptosis regulator) or Bim (Bcl-2 interacting mediator, also known as BCL2L11 or BCL2-like 11), the antilethal protein can be Bcl-2 (B-cell / CLL lymphoma 2, also known as BCL2 apoptosis regulator) or Bcl-xL (B-cell lymphoma-extra large, also known as BCL2L1 or BCL2-like 1), which are apoptosis-suppressing proteins.
[0048] Preferably, the first miRNA-responsive mRNA, which is the lethal OFF switch, and the antilethal ON switch are introduced into cells substantially simultaneously in the introduction step. In cells in which mmu-miR-126a-3p or hsa-miR-126-3p is activated, expression of the lethal protein encoded by the lethal OFF switch is suppressed. Furthermore, in these cells, expression of the antilethal protein encoded by the antilethal ON switch is activated. As a result, even if a lethal protein leaks from the first miRNA-responsive mRNA, it is inactivated by the antilethal protein, allowing the cell to survive. On the other hand, in cells in which mmu-miR-126a-3p or hsa-miR-126-3p is not activated, expression of the lethal protein encoded by the lethal OFF switch is activated, while expression of the antilethal protein encoded by the antilethal ON switch is suppressed, resulting in the death of the cell. This makes it possible to selectively keep hematopoietic stem cells with activated mmu-miR-126a-3p or hsa-miR-126-3p alive and selectively kill other cells, thereby enabling autonomous selection of hematopoietic stem cells without using equipment such as a cell sorter.
[0049] By carrying out step (i) followed by step (ii), hematopoietic stem cell populations can be distinguished and selected from non-hematopoietic stem cell populations by translation of a marker protein selected to suit the purpose of selection.
[0050] (iii) Culturing step using hematopoietic stem cell proliferation medium The culturing step, which is an optional step following the selection step (ii), is a step of expanding the selected hematopoietic stem cells substantially without causing differentiation. In step (iii), the selected hematopoietic stem cells are expanded by culturing them in a hematopoietic stem cell proliferation medium. The hematopoietic stem cell proliferation medium is not particularly limited as long as it is a medium that allows hematopoietic stem cells to proliferate without causing differentiation. As an example, a medium containing polyvinyl alcohol and not containing serum components or albumin can be used. Commercially available hematopoietic stem cell proliferation medium can also be used. The culture period can be from about 7 days to about 2 months.
[0051] By carrying out step (iii) following step (ii), the highly pure hematopoietic stem cell population can be further expanded. Therefore, compared to conventional techniques, a large amount of highly pure hematopoietic stem cell population can be obtained more efficiently. Because hematopoietic stem cells are undifferentiated cells and prone to fluctuations, there is a great advantage in expanding them immediately before clinical use, such as transplantation.
[0052] The method for selecting hematopoietic stem cells or the method for producing a hematopoietic stem cell population according to the first embodiment of the present invention makes it possible to obtain a cell population of hematopoietic stem cells with a higher purity than with conventional methods using cell surface markers. Furthermore, because it is a method for introducing RNA molecules, there is no risk of genome damage and it is therefore safer than when introducing a DNA construct.
[0053] [Second embodiment: Method for selecting hematopoietic stem cells using two types of miRNA-responsive mRNA switches] According to a second embodiment, the present invention provides a method for producing a hematopoietic stem cell population, which comprises the following step (i): (i) introducing a first miRNA-responsive mRNA switch and a second miRNA-responsive mRNA switch into a cell population.
[0054] Optionally, the method may include the following steps (ii) and / or (iii): (ii) selecting hematopoietic stem cells based on the translation of a first marker protein encoded by the first miRNA-responsive mRNA switch and the translation of a second marker protein encoded by the second miRNA-responsive mRNA switch, and (iii) culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell expansion medium.
[0055] The method for selecting hematopoietic stem cells according to the second embodiment is a method for selecting hematopoietic stem cells using at least two types of miRNA-responsive mRNA switches. The first miRNA-responsive mRNA used in the second embodiment may be the same as the first miRNA-responsive mRNA described in the first embodiment. The second miRNA-responsive mRNA switch comprises: (A) a nucleic acid sequence specifically recognized by any one mouse miRNA sequence selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p, or any one human miRNA sequence selected from hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, and hsa-miR-223-3p; and (B) a nucleic acid sequence encoding a second marker protein. and a second marker protein operably linked thereto, and the second marker protein is different from the first marker protein. Hereinafter, the second miRNA-responsive mRNA switch will be referred to as a second miRNA switch. In the second miRNA-responsive mRNA switch, a miRNA switch having a human miRNA target sequence can be used for introduction into a human cell population, and a miRNA switch having a mouse miRNA target sequence can be used for introduction into a mouse cell population.
[0056] (i) Introduction Step In step (i), the first miRNA switch and the second miRNA switch are introduced into a cell population. The definition of the cell population to be introduced may be the same as in the first embodiment.
[0057] The nucleic acid sequences specifically recognized by any one of the sequences selected from (A) mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p can also be referred to as the target sequences of these mouse miRNAs. All six of these miRNAs are highly active in mouse hematopoietic stem cells. Corresponding miRNAs exist that are highly active in human hematopoietic stem cells. Table 1 below shows the sequences (mouse and human) of the six miRNAs that serve as target sequences for the second miRNA switch.
[0058]
[0059] The sequence of (A) can be designed in the same manner as for the first miRNA switch. Specifically, the target sequence of the miRNA is preferably completely complementary to one of the six miRNAs, but may have a degree of mismatch as defined in the first embodiment.
[0060] The sequence encoding the marker protein (B) can be selected from the same options as those for (b) in the first embodiment, except that the second marker protein is a protein different from the first marker protein.
[0061] The 5'-UTR, coding region, and 3'-UTR of the second miRNA switch can be designed in the same manner as the first miRNA switch in the first embodiment, except that the sequences (A) and (B) are different from the sequences (a) and (b). Modifications of sugar residues, cross-linked structures, and phosphate groups may also be the same as those in the first embodiment.
[0062] The method for introducing the second miRNA switch into a cell population can be any of the methods generally used for introducing RNA molecules into cells, as described in the first embodiment. It is preferable to co-introduce the first miRNA switch and the second miRNA switch into a cell population. This is because the activity ratio of proteins expressed from the two or more co-introduced mRNAs is constant within the cell population.
[0063] (ii) Selection step The selection step, which is an optional step following the introduction step, is a step of selecting hematopoietic stem cells based on the translation of the first and second marker proteins. In this selection step, a lethal protein can be used as a marker protein, and selection can be performed in combination with an antilethal ON switch. In this case, the first and second marker proteins may be the same lethal gene or different lethal genes.
[0064] In step (ii) of this embodiment, a cell population consisting of a plurality of cells into which two types of switches have been introduced can be separated into four different populations and identified based on the translation information of the first and second marker proteins. More specifically, mmu-miR-126a-3p or hsa-miR-126-3p is defined as the first miRNA, and any one mouse miRNA sequence selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p, or hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, When any one human miRNA sequence selected from miR-223-3p and miR-223-3p is defined as the second miRNA, hematopoietic stem cells can be separated and distinguished into a population of first miRNA-positive and second miRNA-positive cells (double positive: DP), a population of first miRNA-positive and second miRNA-negative cells (first miRNA single positive: SP), a population of first miRNA-negative and second miRNA-positive cells (second miRNA single positive: SP), and a population of first miRNA-negative and second miRNA-negative cells (double negative: DN). This allows the selection of hematopoietic stem cell populations with different characteristics defined by the activity of two types of miRNA.
[0065] (iii) Culturing step using hematopoietic stem cell expansion medium The culturing step, which is an optional step following the selection step, is a step of expanding the selected hematopoietic stem cells without substantially differentiating them. Step (iii) according to the second embodiment can be carried out in the same manner as step (iii) according to the first embodiment.
[0066] The hematopoietic stem cell population obtained through steps (i), (ii), and optionally step (iii) of this embodiment can also be referred to as a hematopoietic stem cell population enriched for cells positive for the first miRNA activity and positive or negative for the second miRNA activity. The definitions of the first miRNA and the second miRNA are as explained in the selection step (ii) above. When the second miRNA is mmu-miR-223-3p (mouse) or hsa-miR-223-3p (human), a cell population enriched for cells positive for the first miRNA activity and negative for the second miRNA activity (first miRNA single positive: SP) can be referred to as a hematopoietic stem cell population. This is because hematopoietic stem cells have low expression of mmu-miR-223-3p or hsa-miR-223-3p. When the second miRNA is mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, or mmu-miR-196b-5p (mouse) or hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, or hsa-miR-196b-5p (human), a cell population enriched for cells positive for both the first miRNA and the second miRNA (double positive: DP) can be called a hematopoietic stem cell population. This is because expression of these second miRNAs is high in hematopoietic stem cells. More preferably, the hematopoietic stem cell population is a mouse or human hematopoietic stem cell population that is positive for mmu-miR-126a-3p or hsa-miR-126-3p activity and enriched for cells that are positive for mmu-miR-130a-3p or hsa-miR-130a-3p activity. Most preferably, the hematopoietic stem cell population is a human hematopoietic stem cell population that is positive for hsa-miR-126-3p activity and enriched for cells that are positive for hsa-miR-130a-3p activity. Such cell populations have properties distinct from other cell populations and can be used for in vivo transplantation. In particular, mouse or human hematopoietic stem cell populations that are enriched for miR-126a-3p activity and miR-130a-3p activity have been shown to exhibit high engraftment rates and are capable of producing blood after transplantation into the body.Therefore, this hematopoietic stem cell population is suitable for transplantation into patients with blood-related diseases.
[0067] The method for selecting hematopoietic stem cells or the method for producing a hematopoietic stem cell population according to the second embodiment of the present invention enables more detailed selection that focuses on the activity of different miRNAs, compared to the method according to the first embodiment.
[0068] [Third Embodiment: Hematopoietic Stem Cell Selection Kit] In another embodiment, the present invention relates to a hematopoietic stem cell selection kit. The selection kit includes a first miRNA-responsive mRNA switch and, optionally, a second miRNA-responsive mRNA switch. The first miRNA-responsive mRNA switch and the second miRNA-responsive mRNA switch may be miRNA molecules as described in the selection method above. Optionally, the kit may further include a medium used in hematopoietic stem cell selection, a hematopoietic stem cell growth medium such as a medium containing PVA used in hematopoietic stem cell expansion, and / or instructions for use of the selection kit. The target cell selection kit according to this embodiment allows hematopoietic stem cells to be selected safely and with high accuracy and used for transplantation, etc.
[0069] The present invention will be described in more detail below with reference to examples, which are not intended to limit the scope of the present invention.
[0070] [Experimental Methods] [Mice] C57BL / 6J mice (CD45.2 mice) were purchased from Jackson Laboratory Japan or SLC Japan. B6.CD45.1 congenic mice (CD45.1 mice) were purchased from Sankyo Labo Services. For miRNA activity measurement experiments, 8-12 week-old male CD45.1 or CD45.2 mice were used. For transplantation assays, 8-12 week-old female CD45.2 mice were used as hosts, and 8-12 week-old male CD45.1 mice were used as donors. F1 hybrid offspring of CD45.1 and CD45.2 mice (CD45.1 / CD45.2 mice, female, 8-12 weeks old) were used as competitors. All animal experiments were conducted with the approval of the Animal Care and Use Committee of the Center for iPS Cell Research and Application, Kyoto University.
[0071] Mouse hematopoietic stem cell isolation: Bone marrow was collected from mouse tibias, femurs, and pelvises. Bone marrow cells were stained with an APC-conjugated c-Kit antibody (Thermo Fisher Scientific, 17-1171-83) for 30 minutes. After washing, the cells were treated with Anti-APC MicroBeads (Miltenyi Biotec, 130-090-855) for 15 minutes. c-Kit-positive cells were then enriched using an LS column (Miltenyi Biotec, 130-042-401) and a QuadroMACS Separator (Miltenyi Biotec). Enriched c-Kit positive cells were stained for 30 minutes with a Lineage antibody cocktail [biotinylated CD4 antibody (Thermo Fisher Scientific, 13-0042-81), biotinylated CD8 (Thermo Fisher Scientific, 13-0081-81), biotinylated CD45R (Thermo Fisher Scientific, 13-0452-81), biotinylated TER119 (Thermo Fisher Scientific, 13-5921-81), biotinylated Ly-6G / Ly-6C (Thermo Fisher Scientific, 13-5931-81), biotinylated CD11b (Thermo Fisher Scientific, 13-0112-81), and biotinylated CD127 antibody (Thermo Fisher Scientific, 13-1271-81)]. The cells were then washed and stained for 90 minutes with APC-conjugated c-Kit antibody, PE-conjugated Sca-1 antibody (Thermo Fisher Scientific, 12-5981-81), FITC-conjugated CD34 antibody (Thermo Fisher Scientific, 11-0341-81), PE-Cy7-conjugated CD150 antibody (BioLegend, 115913), and Streptavidin APC-eFluor780 (Thermo Fisher Scientific, 47-4317-82). After washing, the cells were resuspended in PBS containing propidium iodide (Thermo Fisher Scientific, P3566) to remove dead cells.CD150 was analyzed using a FACS Aria II (BD). + CD34 - c-Kit + Sca-1 + Lineage - The fraction was sorted into a 96-well plate containing 200 μL of medium, with 50 cells per well.
[0072] [Culture of mouse hematopoietic stem cells] 1% ITS-X (Thermo Fisher Scientific, 51500-056), 10 mM HEPES (Thermo Fisher Scientific, 15630-080), 1% Penicillin-Streptomycin-Glutamine (Thermo Fisher Scientific, 10378-016), 100 ng ml -1 mouse TPO (Peprotech, AF-315-14), 10 ng ml -1 Cells were cultured in Ham's F-12 Nutrient Mix (Thermo Fisher Scientific, 11765-054) containing mouse SCF (Peprotech, AF-250-03) and 1 mg / mL polyvinyl alcohol (PVA) (Sigma, P8136). They were cultured in 200 μL of medium in a fibronectin-coated 96-well plate (Corning, 354409) at 37°C in a 5% CO2 incubator. Five days after sorting, the medium was changed, and thereafter, the medium was changed every two days.
[0073] [Culturing of human hematopoietic stem cells] Commercially available human umbilical cord blood-derived CD34-positive cells (STEMCELL Technologies, 70008.2) were used as human hematopoietic stem cells. Cells were cultured in IMDM with or without glutamine (Sigma, 3390-500ML) containing 1X penicillin-streptomycin solution (Wako, 168-23191), 1X ITS-X (Thermo Fisher Scientific, 51500056), 4 mM L-glutamine (Thermo Fisher Scientific, 25030149), 0.1 mg / mL Soluplus (BASF, 50539897), 1 μM UM729 (STEMCELL Technologies, 72332), 5 μM 740 YP (MedChemExpress, HY-P0175), 0.2 μM butyzamide (Shionogi), and 10 ng / mL Human Flt3-Ligand (Shenandoah Biotechnology, 100-21-10UG). The cells were cultured in a Corning CellBIND 24-well plate (Corning, 3337) containing 1 mL of medium in a 37°C, 5% CO2 incubator. The medium was changed every 3 days.
[0074] [mRNA synthesis] Template DNA for in vitro transcription (IVT) was synthesized by PCR using a plasmid vector containing the 5'-UTR, an ORF encoding a fluorescent protein, and the 3'-UTR. The PCR product was treated with Dpn I (TOYOBO, DPN-101) and purified using the Monarch PCR & DNA Cleanup Kit (NEB, T1030). mRNA was transcribed using the MEGAscript T7 Transcription Kit (Thermo Fisher Scientific, AM1334). The reaction mixture contained 1× Reaction Buffer (Thermo Fisher Scientific), 6 mM CleanCap AG (3' Ome) (TriLink Biotechnologies, N-7413), 7.5 mM GTP (Thermo Fisher Scientific), 7.5 mM ATP (Thermo Fisher Scientific), 7.5 mM CTP (Thermo Fisher Scientific), 7.5 mM N1-ΨTP (TriLink Biotechnologies, N-1081), 1× T7 Enzyme mix (Thermo Fisher Scientific), and IVT template, and was incubated at 37°C for 10 hours. TURBO DNase (Thermo Fisher Scientific) was added and incubated at 37°C for 30 minutes. The RNA was purified using the Monarch RNA Cleanup Kit (NEB, T2040). The RNA was then dephosphorylated with Antarctic Phosphatase (NEB, M0289) and Antarctic Phosphatase Buffer (NEB) for 30 minutes. Finally, the mRNA was purified using the Monarch RNA Cleanup Kit (NEB, T2040). The primers used for mRNA synthesis are shown in Table 2. The sequences of the plasmid vectors used as templates are shown in SEQ ID NOs: 17 to 40 in the Sequence Listing.
[0075]
[0076] [Electroporation of mRNA into mouse cells] Cultured cells were collected in a 1.5-mL centrifuge tube and centrifuged at 400 × g for 5 minutes. The supernatant was removed, and the cells were resuspended in MaxCyte Electroporation Buffer (MaxCyte, EPB1). mRNA (1250 ng each) and 1 × 10 5 The cells were mixed and added to the wells of an OC-25x3 processing assembly (MaxCyte). Electroporation was performed using MaxCyte STX (MaxCyte). After electroporation, the cells were transferred to a fibronectin-coated 24-well plate (Corning, 354411) containing 0.5-1 mL of medium and cultured at 37°C in a 5% CO2 incubator. miRNA inhibitors were purchased from GeneDesign. For experiments using miRNA inhibitors, 1x10 cells were added. 5 12.5 pmol of miRNA inhibitor per cell was co-electroporated with mRNA.
[0077] [Electroporation of mRNA into human cells] Cultured cells were collected in a centrifuge tube and centrifuged at 400 × g for 5 minutes. The supernatant was removed, and the cells were resuspended in MaxCyte Electroporation Buffer (MaxCyte, EPB1). mRNA (1000 ng or 1250 ng, respectively) and 1 × 10 5 The cells were mixed and added to a well of an OC-25x3 processing assembly (MaxCyte). Electroporation was performed using a MaxCyte STX (MaxCyte). After electroporation, the cells were transferred to a Corning CellBIND 24-well plate (Corning, 3337) containing 1 mL of medium and cultured at 37°C in a 5% CO2 incubator. miRNA inhibitors were purchased from GeneDesign. In experiments using miRNA inhibitors, 20 pmol or 40 pmol of miRNA inhibitor was co-electroporated with mRNA.
[0078] [Flow cytometry of mouse cells] Cultured mouse cells were collected in a 1.5-mL centrifuge tube and centrifuged at 400 × g for 5 minutes. The supernatant was removed, and the cells were resuspended in PBS containing propidium iodide (Thermo Fisher Scientific, P3566) to remove dead cells. For analysis using fluorescently labeled antibodies, the cultured cells were collected in a 1.5-mL centrifuge tube and centrifuged at 400 × g for 5 minutes, and the supernatant was removed. Then, the cells were stained for 30 minutes using a Lineage antibody cocktail [biotinylated CD4 antibody (Thermo Fisher Scientific, 13-0042-81), biotinylated CD8 (Thermo Fisher Scientific, 13-0081-81), biotinylated CD45R (Thermo Fisher Scientific, 13-0452-81), biotinylated TER119 (Thermo Fisher Scientific, 13-5921-81), biotinylated Ly-6G / Ly-6C (Thermo Fisher Scientific, 13-5931-81), and biotinylated CD127 antibody (Thermo Fisher Scientific, 13-1271-81)]. Cells were washed and stained for 30 minutes with PE-conjugated CD201 antibody (Thermo Fisher Scientific, 12-2012-80), PE-Cy7-conjugated Sca-1 antibody (Thermo Fisher Scientific, 25-5981-81), APC-conjugated c-Kit antibody (Thermo Fisher Scientific, 17-1171-83), and Streptavidin APC-eFluor780 (Thermo Fisher Scientific, 47-4317-82). After washing, cells were resuspended in PBS containing propidium iodide (Thermo Fisher Scientific, P3566) to remove dead cells. Analysis was performed using a FACS Aria II (BD). Data were analyzed using FlowJo 10.5.3 (BD).
[0079] [Flow cytometry of human cells] Cultured human cells were collected in a 1.5-mL centrifuge tube and centrifuged at 400 × g for 5 minutes. The supernatant was removed, and the cells were resuspended in PBS containing propidium iodide (Thermo Fisher Scientific, P3566) to remove dead cells. Analysis was performed using a FACS Aria II (BD). Data were analyzed using FlowJo 10.5.3 (BD).
[0080] [Transplantation of hematopoietic stem cells] Hematopoietic stem cells derived from CD45.1 mice were cultured and the desired fraction was sorted using a FACS Aria II (BD). Host CD45.2 mice were irradiated with a lethal dose of radiation (4.9 Gy per dose, two doses with a 4-hour interval) using a Gamma Cell 40 (Best Theratronics). Then, hematopoietic stem cells and 5 × 10 5 Bone marrow cells from 100 CD45.1 / CD45.2 mice were simultaneously transplanted into the host via the tail vein.
[0081] [Peripheral blood analysis] Blood was collected from the facial vein of the recipient at 4, 8, 12, and 16 weeks after transplantation. Peripheral blood samples were treated with RBC Lysis Buffer (pluriSelect, 60-00050-13) and then stained for 30 minutes with CD45.1 antibody conjugated with PE-Cy7 (BioLegend, 110730), CD45.2 antibody conjugated with BV421 (BioLegend, 109832), CD4 antibody conjugated with APC (Thermo Fisher Scientific, 17-0042-83), CD8 antibody conjugated with APC (Thermo Fisher Scientific, 17-0081-83), CD11b antibody conjugated with PE (Thermo Fisher Scientific, 12-0112-82), Gr-1 antibody conjugated with PE (Thermo Fisher Scientific, 12-5931-82), and CD45R antibody conjugated with APC-eFluor780 (Thermo Fisher Scientific, 47-0452-82). After washing, the cells were resuspended in PBS containing propidium iodide (Thermo Fisher Scientific, P3566) to remove dead cells. Analysis was performed using a FACS Aria II (BD).
[0082] [Small RNA-seq] Total RNA was purified using the mirVana miRNA Isolation Kit (Thermo Fisher Scientific, AM1560) according to the instructions provided with the kit. Total RNA was eluted with nuclease-free water. RNA concentration was quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Total RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent). Total RNA was concentrated using a freeze dryer FD-1000 (EYELA). 0.25 μM 3' randomized adapter (5'- App / NNNNTGGAATTCTCGGGTGCCAAGG / ddC -3', purchased from IDT (SEQ ID NO: 41)), 200 units of T4 RNA ligase 2 truncated KQ (NEB, M0373), 1X T4 RNA ligase reaction buffer (NEB), 20% PEG 8000 (NEB), 10 units of SUPERase ・The reaction mixture containing RNase Inhibitor (Thermo Fisher Scientific, AM2694) and total RNA was incubated at 25°C for 16 hours to ligate 3' random adapters to the small RNAs. The ligated RNA was then electrophoresed on a 15% denaturing polyacrylamide gel, and the 40-55 base fraction was excised to remove unreacted adapters. The excised gel pieces were placed in a gel breaker tube (Cosmo Bio) and crushed by centrifugation at 20,400 xg for 10 minutes. The crushed gel pieces were immersed in 0.3 M NaCl (Nacalai tesque, 06900-14) and stirred overnight at 25°C at 1,500 rpm to elute the small RNAs. The eluted RNA was purified by ethanol precipitation using sodium acetate (Nippon Gene, 316-90081) and GlycoBlue Coprecipitant (Thermo Fisher Scientific, AM9515). 0.18 μM 5' randomized adapter (5'- G*T*T*C*A*G*A*G*T*T*C*T*A*C*A*G*T*C*C*G*A*C*rGrArUrCr(N:25252525)r(N)r(N)r(N) -3', purchased from IDT (SEQ ID NO: 42)), 14 units of T4 RNA ligase 1 (NEB, M0204), 1X T4 RNA ligase reaction buffer (NEB), 20% PEG 8000 (NEB), 1 mM ATP (NEB), 14 units of SUPERase ・The reaction mixture containing purified RNA and RNase Inhibitor (Thermo Fisher Scientific, AM2694) was incubated at 37°C for 1 hour for adapter ligation, followed by 15 minutes at 65°C to inactivate the enzyme. The reaction mixture contained 200 units of SuperScript III reverse transcriptase (Thermo Fisher Scientific, 18080085), 1X first-strand buffer (Thermo Fisher Scientific), 0.2 μM RT primer (RTP, GCCTTGGCACCCGAGAATTCCA (SEQ ID NO: 43)), 0.5 mM dNTPs (included in the TruSeq Small RNA kit, Illumina), 5 mM DTT (Thermo Fisher Scientific), and the adapter-ligated RNA. The reaction mixture was incubated at 37°C for 1 hour and 70°C for 15 minutes to synthesize cDNA. The cDNA library was amplified using a reaction mixture containing cDNA, 1 unit of Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific, F530), 1X Phusion HF buffer (Thermo Fisher Scientific), 0.5 μM primers (RP1 forward primer and RPI reverse primer from the TruSeq Small RNA kit from Illumina), and 0.2 mM dNTPs (TAKARA) under the following conditions: PCR reaction cycle: 98°C for 30 seconds, (98°C for 10 seconds, 60°C for 30 seconds, 72°C for 15 seconds), 72°C for 10 minutes (repeated 15 times in parentheses). The amplified cDNA library was electrophoresed on a 6% non-denaturing polyacrylamide gel, and products of approximately 150 bp were excised. The cDNA was purified using the ethanol precipitation method described above.The purified cDNA was used as a template in a reaction mixture containing 1 unit of Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific, F530), 1X Phusion HF buffer (Thermo Fisher Scientific), 0.5 μM primers (RP1 forward primer and RPI reverse primer from the TruSeq Small RNA kit from Illumina), and 0.2 mM dNTPs (TAKARA) under the following conditions: PCR reaction cycle: 98°C for 30 seconds, (98°C for 10 seconds, 60°C for 30 seconds, 72°C for 15 seconds), 72°C for 10 minutes (repeated 10 times in parentheses). The amplified cDNA library was electrophoresed on a 6% non-denaturing polyacrylamide gel, and products of approximately 150 bp were excised. The cDNA was purified using the ethanol precipitation method described above. The size of the cDNA library was confirmed using an Agilent 2100 Bioanalyzer (Agilent). The cDNA library concentrations were quantified using KAPA Library Quantification Kits (KAPA Biosystems). Equal amounts of the cDNA libraries were mixed and pooled, and sequencing was performed on the NextSeq 500 platform (Illumina). The NextSeq 500 / 550 High Output Kit v2.5 (75 cycles, Illumina) was used.
[0083] [Results] [Measurement of miRNA activity in ex vivo cultured mouse hematopoietic stem cells] Figure 1 shows an outline of an experiment to measure miRNA activity in ex vivo cultured mouse hematopoietic stem cells using an "miRNA-responsive mRNA switch" that can detect intracellular miRNA activity. First, hematopoietic stem cells (Lineage 1) were selected from mouse bone marrow using fluorescence-activated cell sorting (FACS). - c-Kit + Sca-1 + CD150 + CD34 -) was isolated. The cells were then cultured for two weeks in a medium containing polyvinyl alcohol (PVA). The miR-126a-3p-responsive miRNA switch encoding EGFP and mRNA encoding TagBFP were introduced into the cells cultured for two weeks by electroporation. 24 hours after mRNA introduction, the cells were analyzed using a flow cytometer. In the examples shown in Figures 1 to 15B, a mouse miRNA-responsive switch was used as the miRNA-responsive switch. In the following examples, unless mmu- or hsa- is specified, this refers to mouse miRNA.
[0084] Figure 2A shows the results of measuring miR-126a-3p activity in mouse hematopoietic stem cells cultured in vitro for two weeks. The plots show EGFP vs. TagBFP plots and histograms of EGFP / TagBFP values for cells transfected with control EGFP mRNA (top panel) and cells transfected with the miR-126a-3p-responsive miRNA switch (bottom panel). EGFP / TagBFP is calculated by dividing EGFP fluorescence intensity by TagBFP fluorescence intensity to correct for differences in electroporation efficiency between cells. EGFP expression is suppressed in a subset of cells transfected with the miR-126a-3p-responsive miRNA switch. A gate was set to define miR-126a-3p-positive cells (cells in which EGFP expression is suppressed) based on the histogram of cells transfected with control EGFP mRNA. Figure 2B shows the percentage of miR-126a-3p-positive cells. n=2. Black bars represent the average of two independent experiments. Differential miR-126a-3p activity was observed in cultured mouse hematopoietic stem cell populations.
[0085] [Changes in the percentage of miR-126a-3p-positive cells due to miR-126a-3p inhibition] We conducted a validation experiment using a miR-126a-3p inhibitor. Cells were transfected with control EGFP mRNA or a miR-126a-3p-responsive miRNA switch, and simultaneously transfected with a miR-126a-3p inhibitor. Controls included no miRNA inhibitor (no miRNA inhibitor) and a negative control inhibitor (negative control inhibitor). Figure 3A shows a histogram plotting EGFP / TagBFP values on the horizontal axis. Figure 3B shows the percentage of miR-126a-3p-positive cells. In cells transfected with the miR-126a-3p-responsive miRNA switch, the percentage of miR-126a-3p-positive cells decreased with the introduction of a miR-126a-3p inhibitor. n=2. Black bars represent the average of two independent experiments.
[0086] [Enrichment of hematopoietic stem cells defined by surface markers by miR-126a-3p] Cells transfected with control EGFP mRNA or the miR-126a-3p-responsive miRNA switch were stained with fluorescently labeled antibodies and analyzed by flow cytometry. Sca-1 vs c-Kit plots and FSC-A vs EPCR plots for cells transfected with the miR-126a-3p-responsive miRNA switch are shown in Figure 4. Compared with the unseparated bulk population and miR-126a-3p-negative cells, miR-126a-3p activity-positive cells contained a fraction considered to be enriched for hematopoietic stem cells defined by the expression pattern of cell surface antigens, namely c-Kit. + Sca-1 + Lineage - : KSL and EPCR + It was confirmed that the KSL fraction was concentrated.
[0087] [Hematopoietic stem cells identified by surface markers after ex vivo expansion] Mouse hematopoietic stem cells expanded in vitro can be enriched by hierarchical gating based on the expression pattern of cell surface antigens. In a previous study (Che et al., EMBO Rep., 2022, doi: 10.15252 / embr.202255502), mouse hematopoietic stem cells expanded in a medium containing PVA expressed c-Kit. + Sca-1 + Lineage - EPCR + (EPCR + Figure 5A shows that expanded mouse hematopoietic stem cells are contained in the EPCR (KSL) fraction. + Figure 5B is a schematic diagram showing that EPCR is contained in the KSL fraction. + As shown in the right panel of Figure 5B, functional hematopoietic stem cells express EPCR. + It is concentrated in the KSL fraction.
[0088] [miR-126a-3p activity in hematopoietic stem cell fractions defined based on the expression patterns of cell surface markers] Figure 6 shows the activity of miR-126a-3p in hematopoietic stem cells defined based on the expression patterns of cell surface markers. + The percentage of miR-126a-3p activity-positive and -negative cells in the KSL fraction is shown. + It was confirmed that miR-126a-3p activity was heterogeneous in the KSL fraction, and that it contained cells that were positive and negative for miR-126a-3p activity.
[0089] [Bone marrow reconstitution ability of miR-126a-3p+ cells and miR-126a-3p- cells] Figure 7 shows an outline of an experiment evaluating the function of miR-126a-3p activity-positive and -negative cells using a transplantation assay. Hematopoietic stem cells collected from CD45.1 B6 mice were cultured in vitro for 2 weeks and then transfected with mRNA by electroporation. The day after mRNA transfection, cells transfected with the miR-126a-3p-responsive miRNA switch and TagBFP mRNA were divided into TagBFP-positive cells that were not sorted for miR-126a-3p activity (Unsorted), and TagBFP-positive cells that were miR-126a-3p activity-positive (miR-126a-3p- + ) or TagBFP-positive but miR-126a-3p activity-negative cells (miR-126a-3p - ) were sorted by FACS. 3,000 sorted cells were added to 5 × 10 5 The mice were transplanted into lethally irradiated C57BL / 6J mice (CD45.2 B6 mice) via the tail vein along with bone marrow cells. Irradiation was performed using a Gammacell® 40 Exactor at 4.9 Gy, administered twice, 4 hours apart. Peripheral blood samples were collected from the recipients 4, 8, 12, and 16 weeks after transplantation and analyzed by flow cytometry.
[0090] The results of peripheral blood analysis after transplantation are shown. Figure 8A is a graph showing the change in peripheral blood chimerism (PB chimerism %) over the number of weeks since transplantation. miR-126a-3p activity-positive cells (miR-126a-3p + ) transplanted mice were divided into cells that were not separated into miR-126a-3p activity positive / negative (Unsorted) and miR-126a-3p activity negative cells (miR-126a-3p - ) showed higher peripheral blood (PB) chimerism than mice transplanted with unsorted miR-126a-3p. + cells, and miR-126a-3p - 1 is a graph showing peripheral blood chimerism (PB chimerism %) 16 weeks after transplantation in cells. Unsorted, miR-126a-3p +, miR-126a-3p - In mice that received either of these transplants, it was confirmed that three types of cells derived from the donor cells, myeloid, B cells, and T cells, were produced in the peripheral blood.
[0091] [miR-126a-3p in hematopoietic stem cell populations defined based on cell surface marker expression patterns + / - Bone marrow reconstitution potential of cells] EPCR positive for miR-126a-3p activity by transplantation assay + KSL cells or EPCR negative for miR-126a-3p activity + The function of KSL cells was evaluated. miR-126a-3p activity-positive EPCR + KSL cells (EPCR + KSL miR-126a-3p + ) or miR-126a-3p activity negative EPCR + KSL cells (EPCR + KSL miR-126a-3p - ) were sorted by FACS. 3,000 sorted cells were added to 5 × 10 5 The cells were transplanted into lethally irradiated C57BL / 6J mice (CD45.2 mice) via the tail vein along with bone marrow cells. Peripheral blood samples were collected from the hosts 4, 8, 12, and 16 weeks after transplantation and analyzed using flow cytometry. Figure 9A illustrates the experimental scheme. Figure 9B is a graph showing the progress of peripheral blood chimerism (PB chimerism %) over the number of weeks since transplantation. EPCR + KSL miR-126a-3p + Mice transplanted with EPCR + KSL miR-126a-3p - The mice transplanted with EPCR showed higher peripheral blood chimerism than those transplanted with IgG. + KSL miR-126a-3p + Cells, and EPCR + KSL miR-126a-3p -This is a graph showing peripheral blood chimerism (PB chimerism %) in cells 16 weeks after transplantation. It was confirmed that three lineages of cells derived from donor cells, myeloid, B cells, and T cells, were produced in the peripheral blood.
[0092] [EPCR + KSL, EPCR - KSL, and Sca-1 - Lineage - miRNA expression profile in fractions] Figure 10 shows the miRNA expression profile in fractions obtained using EPCR with Small RNA-seq. + KSL, EPCR - KSL, Sca-1 - Lineage - In a quantitative experiment of miRNA expression levels in fractions, EPCR was performed on mouse hematopoietic stem cells cultured in vitro for 2 weeks. + KSL, EPCR - KSL, Sca-1 - Lineage - Gating for fraction collection is shown. EPCR + KSL and EPCR - A comparative analysis of miRNA expression levels in KSL was performed, and EPCR + KSL and EPCR - We selected miRNAs whose expression levels were significantly different between KSLs.
[0093] More specifically, we sorted the following three fractions and isolated total RNA from these fractions from three independent cultures: (1) Sca-1; - Lineage - (2) EPCR+KSL (3) EPCR-KSL
[0094] AQ-seq libraries were prepared using a modified AQ-seq protocol. MiRNAs differentially expressed between EPCR+KSL and EPCR-KSL were analyzed to select candidate miRNAs for downstream screening using the miRNA switch. The selection criteria were as follows: (1) The average RPM of at least one of the three fractions was 1,000 or higher across three biological experiments. (2) The miRNAs were significantly expressed between EPCR+KSL and EPCR-KSL (adjp < 0.1).
[0095] EPCR + KSL and EPCR - Table 3 shows several candidate miRNAs whose expression levels are significantly altered between KSLs, and their sequence numbers. - Compared to KSL, EPCR + Highly expressed miRNAs are indicated as UP in KSL, and EPCR - Compared to KSL, EPCR + miRNAs with low expression levels in KSL were indicated as DOWN.
[0096]
[0097] EPCR using small RNA-seq + KSL, EPCR - KSL, Sca-1 - Lineage - The results of quantification of miRNA expression levels in the fractions are shown in Figures 11A and 11B. In each graph, the vertical axis represents miRNA expression levels (RPM: Reads per million mapped reads). A higher RPM indicates a higher relative miRNA expression level. Dots represent individual data points, and bars represent the average of three biological experiments.
[0098] EPCR using small RNA-seq + KSL, EPCR - KSL, Sca-1 - Lineage - The continuation of the quantification results of miRNA expression levels in the fractions is shown in Figures 12A and 12B.
[0099] [Measurement of activity of multiple candidate miRNAs] We performed an experiment to measure the activity of miRNAs selected from the miRNA expression level analysis using small RNA-seq. First, hematopoietic stem cells (lineage 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, - c-Kit + Sca-1 + CD150 + CD34 - ) were isolated and then cultured in PVA-containing medium for two weeks. The miRNA switch encoding EGFP and mRNA encoding TagBFP (a control mRNA that does not respond to miRNA) were introduced into the cells by electroporation. 24 hours after mRNA introduction, the cells were analyzed using a flow cytometer.
[0100] The results of the experiment to measure the activity of miRNAs selected from the miRNA expression level analysis using Small RNA-seq method were as follows: For EGFP, miR-126a-3p, let-7e-5p, let-7k, miR-10a-5p, miR-126a-5p, miR-130a-3p, miR-30a-3p, miR-99a-5p, miR-125a-5p, miR-125b-5p, miR-155-5p, and miR-196b-5p, miR-17-5p, miR-18a-5p, miR-20a-5p, miR-92a-3p, miR-142a-3p, miR-181a-5p, miR-223-3p, and miR-340-5p, plots were obtained with the expression level of EGFP on the vertical axis and the expression level of TagBFP on the horizontal axis (not shown).
[0101] Figure 13A shows a histogram of EGFP / TagBFP values on the vertical axis obtained in an experiment measuring the activity of miRNAs selected from miRNA expression level analysis using Small RNA-seq. Representative examples include histograms of cells transfected with control EGFP mRNA or the miR-126a-3p-responsive miRNA switch (Figure 13A). Bar graphs showing the coefficient of variation (CV) of EGFP / TagBFP values in cell populations transfected with each of several candidate miRNAs are shown (Figures 13B and 13C). Among the candidate miRNAs, miRNAs showing high CV values are considered to be miRNAs with high heterogeneity in activity in ex vivo-expanded mouse hematopoietic stem cells (Figures 13B and 13C).
[0102] [Experiment for simultaneous measurement of activity of multiple miRNAs] An experiment for simultaneous measurement of activity of two types of miRNA was carried out. First, hematopoietic stem cells (Lineage 1) were isolated from mouse bone marrow using fluorescence-activated cell sorting (FACS). - c-Kit + Sca-1 + CD150 + CD34 - ) were isolated and then cultured in PVA-containing medium for two weeks. The miRNA switches encoding EGFP (responsive to miR-126a-3p, miR-155-5p, miR-196b-5p, miR-130a-3p, miR-10a-5p, miR-126a-5p, or miR-223-3p), the miR-126a-3p-responsive miRNA switch encoding mT-Sapphire, and mRNA encoding TagBFP were electroporated into the cells. Cells were analyzed using a flow cytometer 24 hours after mRNA transfection.
[0103] The results of the experiment to simultaneously measure the activities of two types of miRNAs are shown in plots with the EGFP / TagBFP value on the vertical axis and the mT-Sapphire / TagBFP value on the horizontal axis (Figures 14A and 14B).
[0104] [miR-126a-3p + and miR-126a-3p -After introducing the miRNA switch into hematopoietic stem cells cultured in a PVA-containing medium, cells positive or negative for miR-126a-3p activity were sorted and then cultured again in a PVA-containing medium to compare their proliferation. Figure 15A shows the results after culturing 250 cells, and Figure 15B shows the results after culturing 500 cells. The cells were harvested, diluted 2-fold with trypan blue, and counted using a Countess III (Thermo Fisher Scientific). miR-126a-3p activity-positive cells (miR-126a-3p + ) are miR-126a-3p activity-negative cells (miR-126a-3p - ), untreated cells that had not been transfected with mRNA (Untreated), and cells transfected with control EGFP mRNA and TagBFP mRNA (EGFP+TagBFP).
[0105] [Selection of mouse hematopoietic stem cells using two types of miRNA activity] Mouse bone marrow-derived hematopoietic stem cells (Lineage 1) were isolated using fluorescence-activated cell sorting (FACS). - c-Kit + Sca-1 + CD150 + CD34 - ) were cultured in medium containing PVA for 2 weeks. The miR-126a-3p-responsive miRNA switch encoding mT-Sapphire, the miR-130a-3p-responsive miRNA switch encoding EGFP, and mRNA encoding TagBFP were then electroporated into hematopoietic stem / progenitor cells. A schematic diagram is shown in Figure 16A. FACS analysis and cell sorting were performed 24 hours after mRNA transfection.
[0106] Figure 16B shows miR-126a-3p + miR-130a-3p + Fractionation and miR-126a-3p + miR-130a-3p -Gating for FACS sorting of fractions is shown. Gates were set to separate positive and negative populations for each miRNA based on controls containing inhibitors for miR-126a-3p and miR-130a-3p.
[0107] Figure 16C shows the expression of miR-126a-3p in a transplantation assay. + miR-130a-3p + Cells and miR-126a-3p + miR-130a-3p - The outline of the cell function evaluation experiment is shown below. Hematopoietic stem cells collected from CD45.1 B6 mice were cultured in vitro for 2 weeks and then transfected with mRNA by electroporation. The day after mRNA transfection, cells positive for TagBFP and positive for both miR-126a-3p and miR-130a-3p activity (miR-126a-3p + miR-130a-3p + cells), or cells that are TagBFP positive, have positive miR-126a-3p activity, and negative miR-130a-3p activity (miR-126a-3p + miR-130a-3p - 3,000 sorted cells were added to 5 × 10 cells collected from CD45.1 / 45.2 B6 mice. 5 The mice were transplanted into lethally irradiated C57BL / 6J mice (CD45.2 B6 mice) via the tail vein along with bone marrow cells. Irradiation was performed using a Gammacell® 40 Exactor at 4.9 Gy, administered twice, 4 hours apart. Peripheral blood samples were collected from the recipients 4, 8, and 12 weeks after transplantation and analyzed by flow cytometry.
[0108] Figure 16 shows the results of peripheral blood analysis after transplantation. Figure 16D is a graph showing the change in peripheral blood chimerism (PB chimerism %) over time with the number of weeks since transplantation. miR-126a-3p + miR-130a-3p + Mice transplanted with the cells showed increased expression of miR-126a-3p + miR-130a-3p -They showed higher peripheral blood (PB) chimerism than mice that received cell transplants.
[0109] Figure 16E shows miR-126a-3p + miR-130a-3p + cells or miR-126a-3p + miR-130a-3p - 1 is a graph showing peripheral blood chimerism (PB chimerism %) in host mice transplanted with cells 12 weeks after transplantation. + miR-130a-3p + Mice transplanted with the cells showed increased expression of miR-126a-3p + miR-130a-3p - Compared to mice that received transplanted cells, the mice that received transplanted cells showed high peripheral blood (PB) chimerism. In both transplanted mice, it was confirmed that three lineages of cells derived from the donor cells, myeloid, B cells, and T cells, were produced in the peripheral blood.
[0110] [Selection of human hematopoietic stem cells using the miRNA switch] Figure 17A shows an outline of an experiment to measure miRNA activity in human hematopoietic stem progenitor cells (HSPCs) cultured in vitro using the miRNA switch. + Cells (STEMCELL Technologies, 70008.2) were cultured in vitro for two weeks. mRNA encoding the human miRNA switch (responsive to hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-223-3p, or hsa-miR-10a-5p) encoding EGFP and TagBFP were electroporated into the cells. Cells were analyzed using a flow cytometer 24 hours after mRNA transfection.
[0111] Figure 17B shows the results of an experiment measuring the activity of hsa-miR-126-3p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-223-3p, or hsa-miR-10a-5p in human hematopoietic stem progenitor cells. The vertical axis plots EGFP expression levels, while the horizontal axis plots TagBFP expression levels. As a control, the plot on the top left shows cells transfected with EGFP mRNA that does not contain a miRNA target sequence.
[0112] [Selection of human hematopoietic stem cells using two types of miRNA switches] Figure 18A shows an outline of an experiment to simultaneously measure the activity of two types of miRNA in human hematopoietic stem and progenitor cells. + Cells were cultured in vitro for 2 weeks and then electroporated with mRNA encoding the hsa-miR-126-3p-responsive miRNA switch encoding mT-Sapphire, a miRNA switch encoding EGFP and responsive to a second miRNA (hsa-miR-130a-3p, hsa-miR-10a-5p, hsa-miR-126-5p, or hsa-miR-223-3p), and TagBFP. FACS analysis was performed 24 hours after mRNA transfection.
[0113] Figure 18B shows plots of EGFP / TagBFP values on the vertical axis and mT-Sapphire / TagBFP values on the horizontal axis, obtained from an experiment in which the activity of two miRNAs was simultaneously measured in human hematopoietic stem and progenitor cells. The top plot shows plots of cells transfected with a negative control miRNA inhibitor. The bottom plot shows plots of cells transfected with an inhibitor of hsa-miR-126a-3p and an inhibitor of a second miRNA (hsa-miR-130a-3p, hsa-miR-10a-5p, hsa-miR-126-5p, or hsa-miR-223-3p) for gating purposes. The introduction of two miRNA switches enabled visualization of the heterogeneity of human hematopoietic stem and progenitor cells, which could not be visualized by the introduction of a single miRNA switch.
Claims
1. (i) A method for selecting hematopoietic stem cells, comprising the step of introducing a first miRNA-responsive mRNA switch into a cell population, wherein the first miRNA-responsive mRNA switch is an mRNA molecule operably linked to: (a) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p; and (b) a nucleic acid sequence encoding a first marker protein.
2. The step (i) further comprises the step of introducing a second miRNA-responsive mRNA switch into the cell population, the second miRNA-responsive mRNA switch comprising: (A) a nucleic acid sequence specifically recognized by any one of mouse miRNA sequences selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p, or any one of human miRNA sequences selected from hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, and hsa-miR-223-3p; and (B) a nucleic acid sequence encoding a second marker protein, wherein the first marker protein and the second marker protein are different.
3. The method of claim 2, wherein the second miRNA-responsive mRNA switch is co-introduced with the first miRNA-responsive mRNA switch.
4. The method of claim 1, further comprising the step of (ii) selecting hematopoietic stem cells based on the expression level of the first marker protein.
5. The method according to claim 4, further comprising the step of (iii) culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell proliferation medium.
6. The method of claim 2, further comprising the step of (ii) selecting hematopoietic stem cells based on the expression levels of the first and second marker proteins.
7. The method according to claim 6, further comprising the step of (iii) culturing the hematopoietic stem cells selected in step (ii) in a hematopoietic stem cell proliferation medium.
8. The method of claim 1, further comprising, before or after step (i), obtaining a hematopoietic stem cell population selected based on cell surface markers.
9. A method for producing a hematopoietic stem cell population, comprising the step of obtaining a selected hematopoietic stem cell population by the selection method according to claim 1.
10. A kit for selecting hematopoietic stem cells comprising a first miRNA-responsive mRNA switch, wherein the first miRNA-responsive mRNA switch is an mRNA molecule operably linked to: (a) a nucleic acid sequence specifically recognized by mmu-miR-126a-3p or hsa-miR-126-3p; and (b) a nucleic acid sequence encoding a first marker protein.
11. The method further comprises a second miRNA-responsive mRNA switch, the second miRNA-responsive mRNA switch comprising: (A) a nucleic acid sequence specifically recognized by any one of mouse miRNA sequences selected from mmu-miR-10a-5p, mmu-miR-126a-5p, mmu-miR-130a-3p, mmu-miR-155-5p, mmu-miR-196b-5p, and mmu-miR-223-3p, or any one of human miRNA sequences selected from hsa-miR-10a-5p, hsa-miR-126-5p, hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-196b-5p, and hsa-miR-223-3p; and (B) a nucleic acid sequence encoding a second marker protein. and wherein the second marker protein is different from the first marker protein.
12. A hematopoietic stem cell population that is enriched for cells that are positive for mmu-miR-126a-3p or hsa-miR-126-3p activity and positive for mmu-miR-130a-3p or hsa-miR-130a-3p activity.
13. A hematopoietic stem cell population described in claim 12, which is hsa-miR-126-3p activity positive and hsa-miR-130a-3p activity positive, for use in human living donor transplantation.
Citation Information
Patent Citations
Methods for cell-specifically controlling proteins that edit target genes
JP2022112522A
METHOD FOR IDENTIFYING DESIRED CELL TYPE USING miRNA EXPRESSION AS AN INDICATOR
WO2015105172A1
mRNA DESIGN METHOD
WO2017073600A1
Method for expressing protein gene in response to expression of mirna
WO2018003779A1
Method for screening neural progenitor cells
WO2019031595A1
